膀胱癌患者新辅助化疗后病理缓解的性别、种族和民族差异
基于国家癌症数据库9955例接受新辅助化疗和膀胱切除术的肌层浸润性膀胱癌患者,评估病理完全缓解(CR)和死亡率的趋势及种族差异。非西班牙裔白人、非西班牙裔黑人和西班牙裔患者的CR分别为12.6%、10.1%和11.8%(P=0.030),非西班牙裔白人女性达到CR的比值比较低,非西班牙裔黑人患者总体死亡率较高,尤其在残留病变时生存更差。
要点
- 非西班牙裔白人、非西班牙裔黑人和西班牙裔患者的CR分别为12.6%、10.1%和11.8%(P=0.030)。
- 非西班牙裔白人女性达到CR的比值比为0.83(95%CI 0.71-0.97)。
- 非西班牙裔黑人男性和女性的总体死亡率风险比分别为1.21(95%CI 1.01-1.44)和1.25(95%CI 1.03-1.53)。
核心结论
- 研究发现化疗反应存在基于性别和种族或民族的差异,所有种族或民族群体的CR趋势随时间增加,但黑人患者生存更差,尤其在存在残留病变时。
- 需要纳入更多代表性不足的少数族裔的临床研究来验证新辅助化疗反应的生物学差异。
研究设计与样本
- 查询国家癌症数据库,纳入接受新辅助化疗和手术的非转移性肌层浸润性膀胱癌患者,队列共9955例。
- 主要终点为CR和死亡率,采用Cochran-Armitage检验、多变量回归和Kaplan-Meier分析进行评估。
主要发现
- 非西班牙裔黑人患者就诊时更年轻(P<.001)、临床肿瘤分期更高(P<.001)、临床淋巴结分期更高(P=.029)。
- 非西班牙裔白人、非西班牙裔黑人和西班牙裔患者的CR分别为12.6%、10.1%和11.8%(P=.030)。
- 非西班牙裔白人患者CR趋势显著增加(P<.001),非西班牙裔黑人(P=.311)和西班牙裔患者(P=.236)的CR趋势增加未达统计学显著。
- 多变量分析中,非西班牙裔白人女性达到CR的比值比为0.83(95%CI 0.71-0.97);非西班牙裔黑人男性风险比为1.21(95%CI 1.01-1.44)和非西班牙裔黑人女性风险比为1.25(95%CI 1.03-1.53)的总体死亡率更高。
- 达到CR的患者无论种族背景如何均未观察到生存差异;对于残留病变患者,非西班牙裔白人、西班牙裔和非西班牙裔黑人的2年生存概率分别为60.7%、62.5%和51.1%(log-rank P=.010)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要纳入更多代表性不足的少数族裔的临床研究来验证新辅助化疗反应的生物学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate trends and racial variations of pathologic complete response (CR) in patients with muscle-invasive bladder cancer undergoing cystectomy. MATERIALS AND METHODS: The National Cancer Database was queried for patients with non-metastatic muscle-invasive bladder cancer who underwent neoadjuvant chemotherapy and surgery. The primary endpoints, CR and mortality, were evaluated using the Cochran-Armitage test, multivariable regression, and Kaplan-Meier analyses. RESULTS: The cohort comprised 9955 patients. Non-Hispanic Black (NHB) patients were younger (P < .001), had a higher clinical tumor (P < .001), and had higher clinical node (P = .029) stages at presentation. CR for non-Hispanic White (NHW), NHB, and Hispanic patients were 12.6%, 10.1%, and 11.8%, respectively (P = .030). There was a significant increase in CR trends for NHW patients (P < .001) and increases in NHB (P = .311) and Hispanic patients (P = .236). On multivariable analysis, NHW females had lower odds of achieving CR (odds ratio: 0.83, 95% CI: 0.71-0.97); however, NHB males (hazard ratio: 1.21, 1.01-1.44) and NHB females (hazard ratio: 1.25, 1.03-1.53) had higher overall mortality in adjusted analysis. Survival differences were not observed in patients who achieved CR, regardless of racial background; however, for those with residual disease, the 2-year survival probabilities were 60.7%, 62.5%, and 51.1% for NHW, HW, and NHB patients, respectively (log-rank P = .010). CONCLUSION: Our findings revealed differences in chemotherapy response based on gender and race or ethnicity. The CR trends for all racial or ethnic groups increased over time. However, Black patients were found to have worse survival, particularly when residual disease was present. Clinical studies with more underrepresented minorities are needed to verify biological differences in response to neoadjuvant chemotherapy.
引用
- Paster IC, Zeng J, Recio-Boiles A, et al. Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients. Urology. 2023. PMID: 37230271. doi:10.1016/j.urology.2023.03.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。